Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 6, 2011, Pages 682-689

  Yi, Sojeong ^a   Kim, Tae Eun ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

amlodipine; drug drug interaction; fimasartan; pharmacokinetics

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; FIMASARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEADY STATE;

ADULT; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; PYRIMIDINES; RENIN; TETRAZOLES; YOUNG ADULT;

EID: 79958280671     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821795d0     Document Type: Article

References (23)

1. Fimasartan [package insert]. Seoul, South Korea: Boryung Pharmaceutical Co. Ltd.; 2010.
2. Lane A, Bryson EE, Lee J, et al. Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharm Ther. 2005;77:P59.
3. Lane A, DK, Bryson S, et al. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Phar Ther. 2005;77:P58.
4. Evaluation of fimasartan as potential substrate for ABC and SLC transporter system [Internal report]. In: Department of Pharmacology, Yonsei University College of Medicine; 2009.
5. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404. (Pubitemid 35469393)
6. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc. 2003;289:2560-2572. (Pubitemid 37430158)
7. Chrysant SG. The role of angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs. 2010;10:315-320.
8. Da Silva PM. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan. Clin Drug Invest. 2010;30:625-641.
9. Ishimitsu T, Numabe A, Masuda T, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res. 2009;32:962-968.
10. Stangier J, Su CA. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40(pt 1):1347-1354.
11. Endersby CA, Brown EG, Perelman MS. Safety profile of lacidipine: a review of clinical data. J Cardiovasc Pharmacol. 1991;17(Suppl 4): S45-S47.
12. Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 2004;23:1921-1986.
13. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492-2499. (Pubitemid 38720545)
14. Csajka C, Buclin T, Brunner HR, et al. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet. 1997;32:1-29. (Pubitemid 27037846)
15. Bolbrinker J, Huber M, Scholze J et al. Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Fundam Clin Pharmacol 2009;23:767-774.
16. Bhad P, Ayalasomayajula S, Karan R, et al. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. J Clin Pharmacol. E-pub ahead of print, September 21, 2010. DOI: 10.1177/0091270010376963.
17. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587-604. (Pubitemid 351680489)
18. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580. (Pubitemid 47028551)
19. Littlejohn TW III, Majul CR, Olvera R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:207-213.
20. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486-492. (Pubitemid 47313030)
21. Nakamura T, Kawachi K, Saito Y, et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J. 2009;50:501-512.
22. Valcarcel Y, Jimenez R, Aristegui R, et al. Effectiveness and safety of amlodipine in newly diagnosed hypertensive patients and in previously diagnosed hypertensive patients not controlled with their usual treatment (NOTA study). Clin Drug Invest. 2003;23:761-770. (Pubitemid 38037264)
23. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/ valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EXEFFeCTS Study. J Am Soc Hypertens. 2008;2:294-302.